Literature DB >> 19749373

Inhibition of influenza virus by baculovirus-mediated shRNA.

Hitoshi Suzuki1, Hiroshi Saitoh, Tomoyuki Suzuki, Hiroshi Takaku.   

Abstract

Influenza viruses A and B cause widespread infections of the human respiratory tract; however, existing vaccines and drug therapy are of limited value for their treatment. Here we show that bispecific short hairpin small-interfering RNA constructs containing an eight-nucleotide intervening spacer, targeted against influenza virus A or influenza virus B, can inhibit the production of both types of virus in infected cell lines. This multiple vector showed remarkable ability to cope with both influenza virus A or B. Furthermore, the Autographa californica multiple nuclear polyhedrosis virus can infect a range of mammalian cells, facilitating its use as a baculovirus vector for gene delivery into cells. In this study, baculovirus-mediated bispecific short-hairpin RNA expression markedly inhibited both influenza virus A and B production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749373     DOI: 10.1093/nass/nrp144

Source DB:  PubMed          Journal:  Nucleic Acids Symp Ser (Oxf)        ISSN: 0261-3166


  3 in total

Review 1.  Selective gene silencing by viral delivery of short hairpin RNA.

Authors:  Katja Sliva; Barbara S Schnierle
Journal:  Virol J       Date:  2010-09-21       Impact factor: 4.099

2.  Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection.

Authors:  Alexander S Timin; Albert R Muslimov; Aleksandra V Petrova; Kirill V Lepik; Maria V Okilova; Andrey V Vasin; Boris V Afanasyev; Gleb B Sukhorukov
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 3.  Insight into alternative approaches for control of avian influenza in poultry, with emphasis on highly pathogenic H5N1.

Authors:  E M Abdelwhab; Hafez M Hafez
Journal:  Viruses       Date:  2012-11-19       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.